CYP19A1, also known as aromatase, is an important enzyme that produces estrogen. By regulating estrogen levels, CYP19A1 affects a variety of processes in the body, including fat production and distribution, bone density, female fertility and brain function. Estrogen deficiency is associated with diseases such as osteoporosis, hardening of the arteries, and Alzheimer’s. Furthermore, CYP19A1 gene variants are associated with migraines and the growth of estrogen-sensitive cancers. In this post, you will find information about aromatase function, gene variants, and natural substances that decrease its activity.

CYP19A1

bigstock-Estrogen-Word-Display-On-Table-88659221-min

Aromatase (CYP19A1) is one of the cytochrome P450 monooxygenases (CYPs) (R).

Many CYPs eliminate toxins and drugs from the human body. However, some, like CYP19A1, are not involved in detoxification but in steroid hormone production.

Read more about CYPs here.

CYP19A1 Function

Aromatase, is a key enzyme in estrogen production. It converts androstenedione and testosterone to estrone and estradiol, respectively (R).

CYP19A1 Location

This enzyme is found in the ovaries, placenta, testis, fat tissue, brain, liver, muscles and hair follicles (R, R, R).

CYP19A1 The Good

By regulating estrogen production, CYP19A1 affects a variety of processes in the body, such as fat production and distribution (R), bone density (R), female fertility (R) and brain function (R).

Estrogen deficiency is associated with a variety of diseases, including osteoporosis, hardening of the arteries (atherosclerosis), and Alzheimer’s disease (R).

CYP19A1 is also involved in the sexual development of the brain (R). How the brain develops and functions depends on the levels of sex hormones it is exposed to.

Furthermore, CYP19A1 also affects cognitive function. It is implicated in reading, speech, and language (R). Estrogen has important roles in learning and memory by enhancing neuron structure and function (R).

Mutations in CYP19A1 are associated with dyslexia (3423 subjects) (R).

Finally, a 38% reduction in CYP19A1 function was observed in patients with autism spectrum disorder (26 subjects) (R).

CYP19A1 The Bad

Increased aromatase activity, resulting in higher estrogen, promotes the growth of estrogen-sensitive cancers.

CYP19A1 Gene Polymorphism

To date, hundreds of CYP19A1 variants have been identified (R).

However, complete CYP19A1 enzyme deficiency is very rare. To date, only 24 cases have been reported (R, R).

Clinical features of CYP19A1 deficiency include:

  • maternal virilization in pregnancy (male-pattern hair growth and other masculine physical traits) due to the excess of androgens and lack of estrogens coming from the fetus. These resolve gradually after giving birth (R).
  • Women have virilized external genitalia, hemorrhagic ovarian cysts in childhood, primary amenorrhea (absence of menstruation), no breast development and decreased bone density (R).
  • Men usually have osteoporosis due to impaired bone mineralization. They also may have abnormal testis size and sperm production, metabolic syndrome-like stomach obesity and insulin resistance (R).
  • RS10046

Having rs10046 (T) increases CYP19A1 levels (resulting in more estrogen) (R).

T/T contributes to hypertension (elevated blood pressure) (2250 and 443subjects) (R, R).

Having T/T also increases migraine susceptibility (283 subjects) (R).

On the other hand, C/C is associated with higher apo B, insulin, BMI, and HOMA index (2250 subjects) (R).

Patients with C may also be more prone to heart disease (189 subjects) (R).

rs1004982 C/C increases the risk of breast cancer (1958 subjects) (R).

rs1902584 A carrier women have a higher waist-to-hip ratio (they are more prone to obesity) (1241 subjects) (R).

C carriers among men (those with either T/C or C/C) have a 1.5 times higher risk of having low bone mineral density (2392 subjects) (R).

rs1902584 T carrier women have a higher waist-to-hip ratio (they are more prone to obesity) (1241 subjects) (R).

Having A/A reduces the risk of rectal cancer (791 cases, 999 controls) (R).

Women with rs28566535 C/C have an increased breast cancer risk (1958 subjects) (R).

T carriers have a higher risk of endometriosis (262 patients and 275 controls) (R).

The common rs4646 C variant increases estrogen levels and may be predispose women to female pattern hair loss (955 subjects) (R).

On the other hand, the T variant for the rs4646 was associated with advanced stage of breast cancer at the time of presentation and a more progressive disease (327 patients) (R).

Woman A/A carriers have higher bone mineral density (256 subjects) (R).

Having rs4775936 G/G increases the risk of breast cancer (1958 subjects) (R).

Also, blood pressure was higher in men, but lower in women with the G/G (218 patients and 225 controls) (R).

Women A carriers had a greater risk of having higher blood pressure (639 subjects) (R).

This variant was associated with endometrial cancer risk in postmenopausal women (1,040 patients and 1,031 controls) (R, R).

Patients with rs700519 T/T had lower breast cancer survival (1,136 patients) (R).

The C variant produces 10–20% more estrogen in postmenopausal women (R).

rs727479 C may increase the risk of lung cancer (529 patients and 567 controls) (R).

Carrying an A, on the other hand, increases the risk of endometrial cancer (10 studies, 4,998 cases and 8,285 controls) (R).

rs749292 produces 10–20% more estrogen in postmenopausal women (R).

The A variant increases the risk of endometrial cancer (10 studies, 4,998 cases and 8,285 controls) (R) and ovarian cancer (367 cases and 602 controls) (R).

Women with rs936306 T/T may have an increased risk of breast cancer (1958 subjects) (R).

  • RS700158

rs700158 G variant is a risk factor for preeclampsia (a pregnancy complication) (286) (R).

  • RS11632903 and RS1902586

rs11632903 and rs1902586 are moderately associated with dyslexia (3423 subjects) (R).

  • RS3751592

G in rs3751592 was associated with the incidence of Alzheimer’s disease (463 subjects) (R).

  • RS11575899

This variant (del/del) was significantly associated with melanoma (117 cases and 116 controls) (R).

Increasing or Decreasing CYP19A1

These increase CYP19A1:

These decrease CYP19A1:

These can both increase and decrease CYP19A1:

FDA Compliance

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.

HOW WOULD YOU RATE THIS ARTICLE?

1 Star2 Stars3 Stars4 Stars5 Stars 1 Total Votes Loading...
TWEET
0

1 COMMENT

  • Ben

    Do you not recommend taking quercetin to reduce cyp19a1?

  • Leave a Reply

    Your email address will not be published. Required fields are marked *